The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs

Infection and Immunity

Volumn 72, Issue 11, 2004, Pages 6622-6632

  Brandt, Lise ^a   Skeiky, Yasir A W ^b   Alderson, Mark R ^b   Lobet, Yves ^c   Dalemans, Wilfried ^c   Turner, Oliver C ^a   Basaraba, Randall J ^a   Izzo, Angelo A ^a   Lasco, Todd M ^a   Chapman, Philip L ^a   Reed, Steven G ^b   Orme, Ian M ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BCG VACCINE; DNA VACCINE; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; MTB32 ANTIGEN; MTB39 ANTIGEN; POLYPROTEIN; POLYPROTEIN MTB72F; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AEROSOL; AIRWAY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BCG VACCINATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GUINEA PIG; HEALING; HISTOLOGY; IMMUNE RESPONSE; LUNG; LUNG GRANULOMA; LUNG TUBERCULOSIS; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TH1 CELL;

ANIMALS; BACTERIAL PROTEINS; BCG VACCINE; GUINEA PIGS; HUMANS; IMMUNIZATION, SECONDARY; LUNG; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; POLYPROTEINS; RECOMBINANT PROTEINS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY; VACCINATION; VACCINES, SYNTHETIC;

EID: 7044235500     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.72.11.6622-6632.2004     Document Type: Article

References (24)

1. Baldwin, S. L., C. D'Souza, A. D. Roberts, B. P. Kelly, A. A. Frank, M. A. Lui, J. B. Ulmer, K. Huygen, D. M. McMurray, and I. M. Orme. 1998. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect. Immun. 66:2951-2959.
2. Behr, M. A., and P. M. Small. 1997. Has BCG attenuated to impotence? Nature 389:133-134.
3. Behr, M. A., and P. M. Small. 1999. A historical and molecular phylogeny of BCG strains. Vaccine 17:915-922.
4. Behr, M. A., M. A. Wilson, W. P. Gill, H. Salamon, G. K. Schoolnik, S. Rane, and P. M. Small. 1999. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284:1520-1523.
5. Bloom, B. R., and C. J. Murray. 1992. Tuberculosis: commentary on a reemergent killer. Science 257:1055-1064.
6. Bojang, K. A., P. J. Milligan, M. Pinder, L. Vigneron, A. Alloueche, K. E. Rester, W. R. Ballou, D. J. Conway, W. H. Reece, P. Gothard, L. Yamuah, M. Delchambre, G. Voss, B. M. Greenwood, A. Hill, K. P. McAdam. N. Tornieporth, J. D. Cohen, and T. Doherty. 2001. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358:1927-1934.
7. Britton, W. J., and U. Palendira. 2003. Improving vaccines against tuberculosis. Immunol. Cell Biol. 81:34-45.
8. Brooks, J. V., A. A. Frank, M. A. Keen, J. T. Bellisle, and I. M. Orme. 2001. Boosting vaccine for tuberculosis. Infect. Immun. 69:2714-2717.
9. Colditz, G. A., T. F. Brewer, C. S. Berkey, M. E. Wilson, E. Burdick, H. V. Fineberg, and F. Mosteller. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271:698-702.
10. Dye, C., S. Scheele, P. Dolin, V. Pathania, and M. C. Raviglione. 1999. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. W.H.O. Global Surveillance and Monitoring Project. JAMA 282:677-686.
11. Feng, C. G., U. Palendira, C. Demangel, J. M. Spratt, A. S. Malin, and W. J. Britton. 2001. Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis. Infect. Immun. 69:4174-4176.
12. Kaufmann, S. H. 2000. Is the development of a new tuberculosis vaccine possible? Nat. Med. 6:955-960.
13. Kirman, J. R., T. Turon, H. Su, A. Li, C. Kraus, J. M. Polo, J. Belisle, S. Morris, and R. A. Seder. 2003. Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A. Infect. Immun. 71:575-579.
14. McMurray, D. N. 2003. Hematogenous reseeding of the lung in low-dose, aerosol-infected guinea pigs: unique features of the host-pathogen interface in secondary tubercles. Tuberculosis (Edinburgh) 83:131-134.
15. Orme, I. M. 1999. Beyond BCG: the potential for a more effective TB vaccine. Mol. Med. Today 5:487-492.
16. Orme, I. M. 2003. The mouse as a useful model of tuberculosis. Tuberculosis (Edinburgh) 83:112-115.
17. Orme, I. M. 1999. New vaccines against tuberculosis. The status of current research. Infect. Dis. Clin. North Am. 13:169-185, vii-viii.
18. Orme, I. M., D. N. McMurray, and J. T. Belisle. 2001. Tuberculosis vaccine development: recent progress. Trends Microbiol. 9:115-118.
19. Raviglione, M. C. 2003. The TB epidemic from 1992 to 2002. Tuberculosis (Edinburgh) 83:4-14.
20. Raviglione, M. C., and A. Pio. 2002. Evolution of W.H.O. policies for tuberculosis control, 1948-2001. Lancet 359:775-780.
21. Rodrigues, L. C., and P. G. Smith. 1990. Tuberculosis in developing countries and methods for its control. Trans. R. Soc. Trop. Med. Hyg. 84:739-744.
22. Skeiky, Y. A. W., M. R. Alderson, J. A. Guderian, P. A. Ovendale, L. Brandt, A. Campos-Neto, Y. Lobet, W. Dalemans, I. M. Orme, and S. G. Reed. 2004. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72f, delivered as naked DNA or as recombinant protein. J. Immunol. 172:7618-7628.
23. Stoute, J. A., M. Slaoui, D. G. Heppner, P. Momin, K. E. Kester, P. Desmons, B. T. Wellde, N. Garcon, U. Krzych, and M. Marchand. 1997. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N. Engl. J. Med. 336:86-91.
24. Turner, O. C., R. J. Basaraba, and I. M. Orme. 2003. Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with Mycobacterium tuberculosis. Infect. Immun. 71:864-871.